WallStSmart

Azitra Inc (AZTR)vsInsmed Inc (INSM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AZTR leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).

AZTR

Avoid

21

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 8.3Quality: 5.0

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AZTRUndervalued (+99.9%)

Margin of Safety

+99.9%

Fair Value

$183.40

Current Price

$0.25

$183.15 discount

UndervaluedFair: $183.40Overvalued

Intrinsic value data unavailable for INSM.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AZTR2 strengths · Avg: 10.0/10
P/E RatioValuation
0.0x10/10

Attractively priced relative to earnings

Price/BookValuation
0.3x10/10

Reasonable price relative to book value

INSM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

AZTR4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.87M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : AZTR

The strongest argument for AZTR centers on P/E Ratio, Price/Book.

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bear Case : AZTR

The primary concerns for AZTR are EPS Growth, Market Cap, Profit Margin.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Key Dynamics to Monitor

AZTR profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

INSM is growing revenue faster at 1.5% — sustainability is the question.

AZTR generates stronger free cash flow (-5M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 21/100). AZTR offers better value entry with a 99.9% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Azitra Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Azitra Inc, a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. The company is headquartered in Branford, Connecticut.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Want to dig deeper into these stocks?